This includes the webinar series (presentations, handouts, and the audience QAs recorded from the live broadcast) and CME/CMLE credit. 


Speakers:

Neal Lindeman, MD Eric H. Bernicker, MD Dara Aisner, MD, PhD
Lynette M. Sholl, MD Sinchita Roy-Chowdhuri, MD, PhD Christopher R. Gilbert, DO, MS, FCCP

 

Series Description: Over the past 10 years, understanding of oncogenic signal transduction pathways has fundamentally altered the treatment paradigm for advanced NSCLC, leading to personalized treatment. As a result, diagnosing and treating NSCLC has evolved from a relatively simple “one-size-fits-all” approach to an extremely complex algorithm that requires personalized treatment plans. 

This free online learning experience is aimed at breaking down barriers to testing and treatment in Non-Small Cell Lung Cancer (NSCLC). Hear from world-renowned experts and explore best practices in test ordering, sample collection, and test interpretation with the goal of improving patient care.

Webinars include: (Click "Topic" tab for descriptions)

  • Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
    Speaker: Neal Lindeman 
    Recorded: May 29, 2018
  • Best Practices in NSCLC Small Specimen Collection for Clinicians 
    Speaker: Eric Bernicker 
    Recorded: June 20, 2018
  • Best Practices in Small Specimen Management for Laboratory Professionals
    Speaker: Dara Aisner
    Recorded: August 16, 2018
  • Liquid Biopsies – Promises and Pitfalls 
    Speaker: Lynette Sholl
    Recorded: October 9, 2018
  • Best Practices in Test Ordering 
    Speakers: Sinchita Roy-Chowdhuri and Christopher R. Gilbert
    Recorded: December 13, 2018

Duration: 5 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: May 29, 2019

Maximum CME/CMLE credit available: 5.0

  • Add the entire series +CME/CMLE into your classroom by clicking "Add to Basket" button located on the right.
  • Add individual webinars +CME/CMLE  into your classroom by clicking on the "Purchase Individual Topics" button on the right. Select the particular webinar(s) that you would like and proceed through checkout.

 

This webinar is a five-part series aimed at breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here.

Supported by an educational grant provided by AstraZeneca


How to claim credit: To earn CME/CMLE credit, all learners must watch the webinars and then complete the online survey. To access the online survey, click "Submit credit" on the course homepage, or click on "My Credit" on the menu to the left.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 5.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 


You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Course Information
Course Date:
May 29, 2018
Course Objectives
  • Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).
  • Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.
  • Identify key obstacles to ensuring adequate tissue availability for molecular analysis in new diagnosis samples of NSCLC.
  • Explain how targeted therapies are selected for patients with advanced adenocarcinoma of the lung.
  • Discuss the need for repeat biopsies upon progression so that therapies that target mechanisms of acquired resistance can be appropriately utilized.
  • Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.
  • Discuss approaches for optimal tissue processing to maximize chances of ensuring successful molecular testing in NSCLC specimens.
  • Elaborate on technical approaches to the specimen handling and laboratory processes which can maximize tissue preservation for molecular testing while maintaining diagnostic integrity.
  • Identify factors that may lead to discrepant results when comparing tumor genomic alterations across platforms or biopsy types.
  • Recognize the biological and technical challenges that limit the sensitivity of liquid biopsy.
  • Identify key obstacles to ensuring adequate specimen collection for molecular analysis in NSCLC patients.
Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision (+CME/CMLE)
\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n
\"\\"\\"\"\"\\"\\"\"
\\n

Speaker:

\\n\\n

Neal Lindeman, MD

\\n
\\n

Moderator:

\\n\\n

Anna Yemelyanova, MD

\\n

 

Description The advent of targeted therapies based on predictive biomarkers has dramatically altered the role of the molecular pathologist in lung cancer patient care. This webinar reviews the new recommendations published in the revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines (Lindeman et al., J Mol Diagn, 2018). This webinar, reviewing the evidence and logic behind the new recommendations, is designed for molecular pathologists, pathologists, oncologists, clinicians, trainees, and multidisciplinary tumor boards to help improve NSCLC patient care. Topics to be covered include recommendations regarding new predictive biomarkers; recommendations for testing for EGFR and ALK TKI resistance; and recommendations regarding new testing methodologies including the use of multiplexed genetic sequencing panels (e.g., NGS testing) to identify other treatment options beyond EGFRALK, and ROS1 as well as cell-free circulating DNA testing for EGFR resistance mutations. The revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines will impact the daily practice of molecular pathologists and clinicians in the care of nearly 150,000 eligible lung cancer patients each year, regardless of whether in a community practice, a large reference lab, or an academic setting, and regardless of their level of expertise or experience.

Duration: 1 hr

Last day to purchase course and claim credit: May 29, 2019

CME/CMLE credit available for this webinar: 1.0

Learning Objectives:

Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).

- Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.

- Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.

Tags
BRAF
EGFR
KRAS
T790M
ROS1
PIK3CA
ERBB2
Practice Guideline
ProductAddPrice
Lindeman (+CME/CMLE)
AMP Member Price:$0.00
Non-Member Price:$0.00
Best Practices in NSCLC Small Specimen Collection for Clinicians (+CME/CMLE)
\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n
\"\\"\\"\"\"\\"\\"\"
\\n

Speaker

\\n\\n

Eric H. Bernicker, MD

\\n
\\n

Moderator

\\n\\n

Christopher R. Gilbert, DO, MS, FCCP

\\n
\\n\\n

Description:

Targeted therapies for advanced lung cancers continue to expand rapidly. Viewers of this presentation will get an overview of the latest developments in the management of oncogene-addicted lung cancers and the need for close collaboration between medical oncologists and pathologists to make sure that patients receive optimal therapy.

Duration: 1 hr

Last day to purchase course and claim credit: May 29, 2019

CME/CMLE credit available for this webinar: 1.0

Learning Objectives:

Explain how targeted therapies are selected for patients with advanced adenocarcinoma of the lung.

- Discuss the need for repeat biopsies upon progression so that therapies that target mechanisms of acquired resistance can be appropriately utilized.

ProductAddPrice
Bernicker (+CME/CMLE)
AMP Member Price:$0.00
Non-Member Price:$0.00
Best Practices in Small Specimen Management for Laboratory Professionals
\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n
\"\\"\\"\"\"\\"\\"\"
\\n

Speaker

\\n\\n

Dara Aisner, MD, PhD

\\n
\\n

Moderator

\\n\\n

Sinchita Roy-Chowdhuri, MD, PhD

\\n
\\n\\n

 

DescriptionThis session will focus on the approaches to management of small tissue samples in the pathology laboratory. These will include diagnostic approaches minimizing use of immunohistochemistry, best practices for maximizing tissue preservation for ancillary studies, and technical considerations for optimal sample use. Additional practices which can be deployed for further tissue maximization will also be discussed.

Duration: 1 hr

Last day to purchase course and claim credit: May 29, 2019

CME/CMLE credit available for this webinar: 1.0

Learning Objectives:

Identify key obstacles to ensuring adequate tissue availability for molecular analysis in new diagnosis samples of NSCLC.

- Elaborate on technical approaches to the specimen handling and laboratory processes which can maximize tissue preservation for molecular testing while maintaining diagnostic integrity.


ProductAddPrice
Aisner (+CME/CMLE)
AMP Member Price:$0.00
Non-Member Price:$0.00
Liquid Biopsies - Promises and Pitfalls
\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n
\"\\"\\"\"\"\\"\\"\"
\\n

Speaker

\\n\\n

Lynette M. Sholl, MD

\\n
\\n

Moderator

\\n\\n

Christina Lockwood, PhD

\\n
\\n\\n

DescriptionThis session will focus on the principles of cell free DNA biology and approaches to detecting genomic alterations in circulating tumor DNA relevant to the diagnosis and management of solid tumor patients. Areas of controversy, as well as technical developments that may expand the use of liquid biopsy in clinical medicine, will be addressed. 

Duration: 1 hr

Last day to purchase course and claim credit: May 29, 2019

CME/CMLE credit available for this webinar: 1.0

Learning Objectives:

  • Recognize the biological and technical challenges that limit the sensitivity of liquid biopsy.

  • Identify factors that may lead to discrepant results when comparing tumor genomic alterations across platforms or biopsy types.

ProductAddPrice
Sholl (+CME/CMLE)
AMP Member Price:$0.00
Non-Member Price:$0.00
Best Practices in Test Ordering
\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n
\"\\"\\"\"\"\\"\\"\"\"\\"\\"\"
\\n

Speaker:

\\n\\n

Sinchita Roy-Chowdhuri, MD, PhD

\\n
\\n

Speaker:

\\n\\n

Christopher R. Gilbert, DO, MS, FCCP

\\n
\\n

Moderator:

\\n\\n

Lynette M. Sholl, MD 

\\n
\\n\\n


DescriptionThis session will focus on clinical questions guiding lung cancer molecular testing and best practices for specimen collection, processing, and handling for maximizing tissue for ancillary studies. A case-based approach will be taken and issues pertaining to tissue collection and processing for adequate diagnostic yield and subsequent ancillary testing will be discussed.

Duration: 1 hr

Last day to purchase course and claim credit: May 29, 2019

CME/CMLE credit available for this webinar: 1.0

Learning Objective:

Identify key obstacles to ensuring adequate specimen collection for molecular analysis in NSCLC patients.

- Discuss approaches for optimal tissue processing to maximize chances of ensuring successful molecular testing in NSCLC specimens.

ProductAddPrice
RoyChowdhuri&Gilbert (+CME/CMLE)
AMP Member Price:$0.00
Non-Member Price:$0.00
Individual topic purchase: Selected
American Medical Association
Continuing Medical Education: 5.00
American Society for Clinical Pathology
CMLE: 5.00
Products
NSCLC Series 1 (+CME/CMLE)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00